COMMUNIQUÉS West-GlobeNewswire

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024

24/04/2024 - 23:25

-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion Program with Grand Opening [...]

Vistin Pharma ASA: Annual Report 2023

24/04/2024 - 23:10

Oslo, Norway, 24 April 2024 Please find attached the Annual Report for 2023 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year results presented on 16 [...]

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

24/04/2024 - 22:51

PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. ( NASDAQ : OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that [...]

Amedisys Reports First Quarter 2024 Financial Results

24/04/2024 - 22:45

BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 [...]

NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24/04/2024 - 22:45

SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

24/04/2024 - 22:40

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal [...]

NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR L’ANNÉE 2023

24/04/2024 - 22:40

L’accord de licence globale de co-développement et de commercialisation avec Janssen Pharmaceutica NV (« Janssen ») étend le potentiel du radioenhancer NBTXR3 à l’échelle internationale. La survie prolongée observée [...]

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24/04/2024 - 22:35

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]

Hapbee Announces Closing of Private Placement

24/04/2024 - 22:33

Company Raises $2.8 Million From Qualified Investors to Fund Product Development, Market Expansion and Manufacturing VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Hapbee Technologies , Inc. (TSXV: HAPB [...]

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

24/04/2024 - 22:30

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the [...]

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24/04/2024 - 22:30

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today [...]

STERIS to Host a Conference Call for Fiscal 2024 Fourth Quarter and Full Year Financial Results on May 9, 2024

24/04/2024 - 22:30

DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year [...]

Entourage Health to Report Fiscal Year 2023 Financial Results

24/04/2024 - 22:16

Company Financials for Full-Year 2023 will be filed after market close on April 29, 2024 TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) ("Entourage" or the " [...]

Spectral AI Schedules 2024 First Quarter Financial Results and Conference Call

24/04/2024 - 22:15

DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]

Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

24/04/2024 - 22:05

ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

24/04/2024 - 22:05

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR [...]

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

24/04/2024 - 22:05

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The [...]

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance

24/04/2024 - 22:05

Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples // Panel significantly accelerates TB outbreak tracking and supports detection [...]

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

24/04/2024 - 22:05

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer [...]